Lung Cancer

Nasim, Faria; Sabath, Bruce F.; Eapen, George A.

doi:10.1016/j.mcna.2018.12.006

Cited by 605 publications

(456 citation statements)

References 45 publications

Supporting

Mentioning

453

Contrasting

Unclassified

Order By: Relevance

“…Worldwide, non-small cell lung cancer (NSCLC) is the most common cause of cancer death [1,2], and more than 70% of patients are found as locally advanced or metastatic disease at the time of diagnosis. Immunotherapy has become a new therapeutic approach in NSCLC with the potential for prolonged benefits [3].…”

Section: Introductionmentioning

confidence: 99%

The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer

Tao

et al. 2020

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Investigate whether 18 F-FDG PET-CT has the potential to predict the major pathologic response (MPR) to neoadjuvant sintilimab in resectable NSCLC patients, and the potential of sifting patients who probably benefit from immunotherapy. Methods Treatment-naive patients with resectable NSCLC (stage IA-IIIB) received two cycles of sintilimab (200 mg, intravenously, day 1 and 22). Surgery was performed between day 29 and 43. PET-CT was obtained at baseline and prior to surgery. The following lean body mass-corrected metabolic parameters were calculated by PET VCAR: SUL max , SUL peak , MTV, TLG, ΔSUL max %, ΔSUL peak %, ΔMTV%, ΔTLG%. PET responses were classified using PERCIST. The above metabolic information on FDG-PET was correlated with the surgical pathology. (Registration Number: ChiCTR-OIC-17013726).Results Thirty-six patients received 2 doses of sintilimab, all of whom underwent PET-CT twice and had radical resection (35) or biopsy (1). MPR occurred in 13 of 36 resected tumors (36.1%, 13/36). The degree of pathological regression was positively correlated with SUL max (p = 0.036) of scan-1, and was negatively correlated with all metabolic parameters of scan-2, and the percentage changes of the metabolic parameters after neoadjuvant therapy (p < 0.05). According to PERCIST, 13 patients (36.1%, 13/36) showed partial metabolic response (PMR), 21 (58.3%, 21/36) had stable metabolic disease, and 2 (5.6%, 2/36) had progressive metabolic disease (PMD). There was a significant correlation between the pathological response and the PET responses which were classified using PERCIST. All (100.0%) the PMR (ΔSUL peak % < − 30.0%) tumors showed MPR. Conclusions 18 F-FDG PET-CT can predict MPR to neoadjuvant sintilimab in resectable non-small cell lung cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer

Tao

et al. 2020

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…The World Health Organization estimated that 1,762,450 new cases of lung carcinoma were detected in 2019 and there were around 606,880 deaths from this disease in that year . Cancer can be treated with radiation, chemotherapy, and surgery . Even though different methods are available to treat cancer, still the death rate from cancer is high.…”

Section: Introductionmentioning

confidence: 99%

“…[5] Cancer can be treated with radiation, chemotherapy, and surgery. [6] Even though different methods are available to treat cancer, still the death rate from cancer is high. The side effects of cancer treatments are also numerous, which limits their application.…”

Section: Introductionmentioning

confidence: 99%

Eco‐friendly synthesis of ZnO nanorods using Cycas pschannae plant extract with excellent photocatalytic, antioxidant, and anticancer nanomedicine for lung cancer treatment

Sudha¹,

Ali²,

Karunakaran

et al. 2020

Applied Organom Chemis

View full text Add to dashboard Cite

The tunable ZnO nanorods (NRs) are produced due to the phytochemicals present in Cycas pschannae leaves which act as reducing and stabilizing agents. The confirmations of the ZnO NRs were validated using different characterization techniques: X‐ray diffraction, Fourier transform infrared spectroscopy, Brunauer, Emmett and Teller (BET), scanning electron microscopy–Energy Dispersive X‐Ray Analysis (EDX), UV–visible spectroscopy, Raman spectroscopy, and transmission electron microscopy. The ZnO NRs show unique surface area and low particle size. Photocatalytic activity was measured and found to be 50.75% at low concentrations and 78.33% at high concentrations. The antioxidant activity of the ZnO NRs also showed promising results for their use in free radical scavenging. In vitro toxicity studies using zebrafish embryos was performed to evaluate the toxic nature of it and the obtained result confirmed its non‐toxic nature. In addition, ZnO anticancer potential was verified using the A549 lung cancer cell line. Cytotoxic assessments of ZnO NRs were performed via 2,3‐bis‐(2‐methoxy‐4‐nitro‐5‐sulfophenyl)‐2H‐tetrazolium‐5‐carboxanilide (XTT), 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl tetrazolium bromide (MTT), and neutral red uptake assays to examine the cell death cycle on the A549 lung cancer cell. Dose‐dependent apoptosis and necrosis were confirmed by Lactate dehydrogenase (LDH) assay. It was also confirmed that ZnO NRs induce Reactive oxygen species (ROS) and apoptosis inside cancer (A549) cells via different intrinsic gene expression. Thus, based on this research it is evident that an effective ecofriendly, nontoxic potential anticancer drug can be synthesized using C. pschannae leaf extract.

show abstract

“…Lung cancer is one of the leading causes of cancer-related deaths worldwide and poses a severe threat to human health [1][2]. The global incidence of lung cancer has increased signi cantly in the past 50 years [3]. Both in developed and developing countries, the prevalence of lung cancer is the highest among all malignant tumors and is related to smoking, occupational carcinogens, air pollution, and ionizing radiation [3].…”

Section: Introductionmentioning

confidence: 99%

“…The global incidence of lung cancer has increased signi cantly in the past 50 years [3]. Both in developed and developing countries, the prevalence of lung cancer is the highest among all malignant tumors and is related to smoking, occupational carcinogens, air pollution, and ionizing radiation [3]. According to histopathology, lung cancer is classi ed into non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) [4].…”

Section: Introductionmentioning

confidence: 99%

Short-and long-term outcomes of video-assisted thoracoscopic lobectomy in elderly patients with non-small-cell lung cancer

Yang

Wang

Ren

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective This study aimed to explore the short-and long-term outcomes of video-assisted thoracoscopic (VATS) lobectomy in older patients with non-small-cell lung cancer (NSCLC). Methods A total of 218 NSCLC patient data between January 2014 and January 2019, which included pathological, clinical, and follow-up surveys on VATS lobectomy, were retrospectively analyzed. Of the 218-patient data analyzed, a total of 77 patients were 70 years of age and older (elderly group), while a total of 141 patients were below 70 years of age (nonelderly group).Results Concerning general preoperative data, the simplified comorbidity score (SCS) and the American Society of Anesthesiologists (ASA) scores were higher in the elderly patient group as compared to the nonelderly patient group. Also, elderly patients had poor pulmonary function performance as compared to their counterparts. There were, however, no significant statistical differences found with surgical data between the two groups concerning intraoperative blood loss, operation duration, and conversion to thoracotomy. None of the patients in either of the groups died within thirty days of the operation. Additionally, there were no significant statistical differences in the five-year overall survival rate and the five-year disease-free survival rate between both groups.Conclusion NSCLC treatment with VATS lobectomy is safe and feasible in elderly patients, and it can provide excellent long-term outcomes. However, it is necessary to strengthen perioperative management and promote early postoperative recovery to reduce complications.

show abstract

Lung Cancer

Cited by 605 publications

References 45 publications

The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer

The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer

Eco‐friendly synthesis of ZnO nanorods using Cycas pschannae plant extract with excellent photocatalytic, antioxidant, and anticancer nanomedicine for lung cancer treatment

Short-and long-term outcomes of video-assisted thoracoscopic lobectomy in elderly patients with non-small-cell lung cancer

Contact Info

Product

Resources

About